

NCIC CLINICAL TRIALS GROUP

LUNG

DISEASE SITE COMMITTEE MEETING AGENDA

FAIRMONT QUEEN ELIZABETH HOTEL, MONTREAL, QC

ROOM: JOLLIET

SUNDAY, MAY 2, 2010 – 8:00 AM – 1:00 PM

CHAIRS: G. GOSS / Y. UNG

-
- | | | |
|----------|--|---|
| 8:00 am | Welcome and Announcements | G. Goss |
| | <ul style="list-style-type: none">Update on site visit and review of research priorities for next 5 yrs | |
| 8:15 am | Subcommittee Reports: | |
| | <ul style="list-style-type: none">Small CellRadiationMesothelioma and ThymomaCorrelative Sciences | P. Ellis
Y. Ung
C. Lee
M. Tsao |
| 9:00 am | Non-Small Cell Lung Cancer: | |
| | <u>Surgical Adjuvant and Neoadjuvant and Locally Advanced Trials</u> | |
| | <ul style="list-style-type: none">BR.19 - Randomized trial of adjuvant gefitinib versus placebo after complete resection of Stage IB, II IIIA NSCLCBRC.2 - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-IIIA NSCLCBRC.5 - CALGB 140503 A Phase III randomized trial of lobectomy versus sub-lobar resection for small (≤ 2cm) peripheral NSCLCBR.16 - Randomized placebo controlled trial of adjuvant selenium in completely resected stage I NSCLC (ECOG) | G. Goss
C. Butts
TBA
TBA |
| 9.45 am | BREAK | |
| 10:05 am | Advanced NSCLC: | |
| | <ul style="list-style-type: none">BR.24 - (Update on Randomized trial of paclitaxel and carboplatin +/- AZD 2171) in advanced Non-SCLC and BRC.4-N0723 – A phase III biomarker validation study of second-line therapy in patients with advanced NSCLC randomized to pemetrexed versus erlotinibBR.29 - A double blind randomized trial of cediranib versus placebo in patients receiving paclitaxel/carboplatin chemotherapy for the treatment of advanced or metastatic Non-Small Cell Lung cancer.BR26 - A double blind placebo controlled trial of PF-804 in advanced NSCLC | G. Goss
S. Laurie
P. Ellis |

continued on next page ...

- 10:35 am **Radiotherapy Study Update:** Y. Ung
- BR.25 - Hypofractionated radiotherapy for medically inoperable NSCLC
 - BRC.1 - PCI in NSCLC
 - BR.27 - LUNG-ART Post-operative adjuvant radiation for completely resected N2 NSCLC
- 10:55 am **Small Cell Lung Cancer:** A. Bezjak
- BR.28 - CONVERT – Once daily versus twice daily radiation for limited SCLC
- 11:05 am **IND Studies:**
- IND.183 - Phase II trial of sunitinib in 2nd-line treatment of malignant mesothelioma S. Laurie
 - IND.190 - Phase I-II trial of etoposide/cisplatin + EGFR1 inhibitor in extensive stage SCLC P. Ellis
 - IND 196 - Phase I/II c-met inhibitor/erlotinib N. Leigh
 - Report from the IND Committee G. Goss
- 11:45 am **PRO, Economic and Secondary Analyses of Lung Trials**
- Quality of Life C. Lee
 - Economic analyses active and planned N. Leigh
 - Database analyses F. Shepherd
- 12:15 pm **New Studies and Close** G. Goss